Literature DB >> 30346708

Pathological Changes of Tau Related to Alzheimer's Disease.

Dandan Chu1, Fei Liu2.   

Abstract

Alzheimer's disease (AD), the most common form of dementia, is characterized by extracellular β-amyloid plaques and intracellular neurofibrillary tangles (NFTs), which are considered as major targets for AD therapies. However, no effective therapy is available to cure or prevent the progression of AD up until now. Accumulation of NFTs, which consist of abnormally hyperphosphorylated tau, is directly correlated with the degree of dementia in AD patients. Emerging evidence indicates that the prion-like seeding and spreading of tau pathology may be the key driver of AD. In the past decades, greater understanding of tau pathway reveals new targets for the development of specific therapies. Here, we review the recent research progress in the mechanism underlying tau pathology in AD and briefly introduce tau-based therapeutics.

Entities:  

Keywords:  Alzheimer’s disease; aggregation; hyperphosphorylation; propagation; tau pathology; truncation

Mesh:

Substances:

Year:  2018        PMID: 30346708     DOI: 10.1021/acschemneuro.8b00457

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  12 in total

1.  Truncation of Tau selectively facilitates its pathological activities.

Authors:  Jianlan Gu; Wen Xu; Nana Jin; Longfei Li; Yan Zhou; Dandan Chu; Cheng-Xin Gong; Khalid Iqbal; Fei Liu
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

2.  Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.

Authors:  Jian-Lan Gu; Fei Liu
Journal:  Curr Med Sci       Date:  2021-01-11

3.  1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimer's Signaling in Human Nerve Cells.

Authors:  Zhibin Liang; Bei Zhang; Meng Xu; Christophe Morisseau; Sung Hee Hwang; Bruce D Hammock; Qing X Li
Journal:  ACS Chem Neurosci       Date:  2019-08-19       Impact factor: 4.418

4.  Dephosphorylation Passivates the Seeding Activity of Oligomeric Tau Derived From Alzheimer's Brain.

Authors:  Ruozhen Wu; Longfei Li; Ruirui Shi; Yan Zhou; Nana Jin; Jianlan Gu; Yunn Chyn Tung; Fei Liu; Dandan Chu
Journal:  Front Mol Neurosci       Date:  2021-05-13       Impact factor: 5.639

Review 5.  The Role of Post-Translational Modifications on the Structure and Function of Tau Protein.

Authors:  Haiqiong Ye; Yue Han; Ping Li; Zhengding Su; Yongqi Huang
Journal:  J Mol Neurosci       Date:  2022-03-24       Impact factor: 2.866

Review 6.  Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis.

Authors:  Hongmei Li; Chia-Chen Liu; Hui Zheng; Timothy Y Huang
Journal:  Transl Neurodegener       Date:  2018-12-24       Impact factor: 8.014

7.  Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease.

Authors:  Jodie B Nichols; Michael Malek-Ahmadi; Pierre N Tariot; Geidy E Serrano; Lucia I Sue; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2021-02-22       Impact factor: 3.685

Review 8.  Role of dietary fatty acids in microglial polarization in Alzheimer's disease.

Authors:  Smita Eknath Desale; Subashchandrabose Chinnathambi
Journal:  J Neuroinflammation       Date:  2020-03-24       Impact factor: 8.322

Review 9.  Proteomics Landscape of Alzheimer's Disease.

Authors:  Ankit P Jain; Gajanan Sathe
Journal:  Proteomes       Date:  2021-03-10

10.  Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease.

Authors:  Xiaoying Jiang; Jianan Guo; Changjun Zhang; Jinping Gu; Tao Zhou; Renren Bai; Yuanyuan Xie
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.